GENFIT, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that affect the liver or the gastrointestinal system, has announced the half-year report of its liquidity contract with CIC.
Under the liquidity contract granted to CIC by GENFIT and BIOTECH AVENIR, the following resources were in the liquidity account as at December 31, 2016:
EUR220,875.34 in cash.
At the last half-year report as at June 30, 2016, the following resources were available in on the liquidity account:
EUR288,225.64 in cash.